Navigation Links
PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
Date:6/13/2013

SAN FRANCISCO and NES-ZIONA, Israel, June 13, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.PROLOR's scientists will present additional pre-clinical and clinical safety data on hGH-CTP and will discuss its manufacturing process.  Data previously reported by the company confirmed that hGH-CTP appears to be safe and well tolerated and that it has the potential to be administered once-weekly to adults with growth hormone deficiency.  The new data provides further information on the excellent safety and tolerability profile of hGH-CTP in a variety of pre-clinical and clinical studies.  PROLOR recently announced that it has initiated a pivotal Phase III study of hGH-CTP in growth hormone deficient adults.

In addition, PROLOR scientists will make an oral presentation discussing MOD-6030, also known as LA-Oxyntomodulin, the company's long-acting GLP-1 and Glucagon dual agonist with potential for the treatment of type 2 diabetes and obesity.  New pre-clinical data will be presented on MOD-6030's effects on weight reduction and glucose tolerance in animal models.

The PROLOR presentations include the following:

FP02-3:  The Long-Acting Dual GLP-1/Glucagon Agonist, Mod-6030, Improves Glycemic Control and Induces a Prolonged Weight Loss in Diet-Induced Obesity Mice Following a Once-Weekly Administration.  See abstract for more information.

SAT-120:  Metabolic and Safety Parameters of Once-Weekly, CTP-
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
2. Law Office of Brodsky & Smith, LLC Announces Investigation of PROLOR Biotech, Inc.
3. OPKO Health To Acquire PROLOR Biotech
4. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
5. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
6. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
7. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
8. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
9. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
10. MedReps.com Report Shows Biotech Workers Earn the Most in Medical Sales
11. Biotechnology Master’s at UMBC Shady Grove - Virtual Info Session to Be Held on June 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015 Forskare ... 2015 på  http://www.openinnovationinscience.at till det återkommande ... som hålls i Wien ... med internationella forskare och vetenskapsmän som genomfördes ... två största utmaningar bristen på incitament för ...
(Date:7/2/2015)... , ... July 03, 2015 , ... Cuvettes have been used in countless labs for ... to find the cuvette they needed. As expected, this was a daunting and tiring ... wrong part because they were not able to navigate the complex catalog structure. , Now ...
(Date:7/2/2015)... ... July 02, 2015 , ... Sleepless nights will become obsolete as Luzi ... its Indiegogo campaign on June 23. Sound sleepers and the sleep deprived both will ... to use, while the integration of the Bluetooth speaker, alarm clock and ability to ...
(Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3New Cuvette E-Commerce Website Launched by FireflySci 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... 5 Delcath Systems, Inc. (Nasdaq: DCTH ... company focused on oncology, highlighted the Phase III trial ... American Society of Clinical Oncology,s 2010 Annual Meeting, comparing ... care for patients with hepatic metastases from ocular or cutaneous ...
... Genomic Health, Inc. (Nasdaq: GHDX ) today ... American Society of Clinical Oncology (ASCO) Annual Meeting, including an ... III colon cancer, suggesting a potential role for the Onco ... III disease, pending further study. The company also announced the ...
... HUNTINGTON BEACH, California and AMSTERDAM , June ... diagnostics, today announced that,researchers from Agendia and leading academic centers ... multiple studies concerning Agendia,s assays,MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the ... 8, 2010 , at McCormick Place in, Chicago . MammaPrint, ...
Cached Biology Technology:Delcath Highlights Phase III Trial Results Presented at ASCO 2Delcath Highlights Phase III Trial Results Presented at ASCO 3Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting 9Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting 2Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting 3
(Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
(Date:6/24/2015)... June 22, 2015 ... addition of the "Huawei Ascend Mate 7 ... to their offering. Huawei,s technological choice ... opposite direction than Apple,s and Samsung,s one. The ... developed by Fingerprint Cards, a main actor in ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... the first time, the upper safe limit of vitamin ... events or death raises significantly, according to a recent ... Journal of Clinical Endocrinology & Metabolism ( JCEM ... plays a pivotal role in human physiology. Vitamin D ...
... in obese laboratory rats may provide a less-invasive alternative ... Endocrinology . Scientists at Cincinnati Children,s Hospital ... of bile from the bile duct into the small ... bariatric surgeries such as gastric by-pass. They named the ...
... the selected highlights for the May 2013 issue of the ... May issue is available online at http://www.genetics.org/content/current . ... 2013. Please feel free to forward to colleagues ... array of topics including: developmental and behavioral genetics; genome integrity ...
Cached Biology News:Researchers pinpoint upper safe limit of vitamin D blood levels 2Study finds possible alternative to bariatric weight loss surgery 2Genetics Society of America's GENETICS journal highlights for May 2013 2Genetics Society of America's GENETICS journal highlights for May 2013 3Genetics Society of America's GENETICS journal highlights for May 2013 4Genetics Society of America's GENETICS journal highlights for May 2013 5
...
... anti-viral agent. Inhibits several important steps of angiogenesis ... HUVEC cells. Also reduces intracellular reactive oxygen species ... of endothelial cells. Formula: ... 8 MolWeight: ...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
Biology Products: